Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Frankenius Equity AB is named as a reporting person in SEC Form 4 filings. OQRO lists 3 transactions filed with the SEC under this name, the latest on Apr 20, 2026, each linked to the official Form 4.
Disclosures on record
3
Companies involved
1
As of the latest filing on , Frankenius Equity AB reported holding 6,989,748 shares of Trisalus Life Sciences (TLSI), worth about $15.9M at the last close of $2 (Nov 16, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Trisalus Life Sciences TLSI | 6,989,748 | 6.99M direct | $2 | $15.9M | Jul 31, 2025 |
Is this Frankenius Equity AB’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median +37.2 pts vs S&P 500, beat it 1 of 1 time.
Average +37.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 19, 2024 to Dec 19, 2024, measured from the first close after the filing. Past results, not a forecast.
Trisalus Life SciencesTLSI
3 disclosures · Dec 2024 – Apr 2026 · 1 bought
Jul 31, 2025759Kdisclosed Apr 20
DetailsOfficial recordJul 31, 2025230Kdisclosed Apr 20
DetailsOfficial recordDec 17, 2024Bought~$250Kdisclosed Dec 19
DetailsOfficial recordOn the latest SEC Form 4, dated Jul 31, 2025, Frankenius Equity AB reported holding 6,989,748 shares of Trisalus Life Sciences (TLSI). At the last close of $2 on Nov 16, 2026, that is about $15.9M. This is the stake disclosed in filings, not a net worth.
Frankenius Equity AB bought shares on the open market in 2024, and has not bought since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
Trisalus Life Sciences (TLSI), from 2024 to 2024: 1 purchase and 0 sales.
Frankenius Equity AB bought shares on the open market in 2024, and has not bought since 2024.
Frankenius Equity AB reported 1 open-market purchase and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $250K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Frankenius Equity AB reported 1 open-market purchase and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.